© 2021 MJH Life Sciences and Pharmacy Times. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmacy Times. All rights reserved.
April 16, 2021
Olaparib and niraparib both show promise in the maintenance treatment of ovarian cancer, though they may each be appropriate for different patient populations.
April 13, 2021
The safety profile was consistent with the profiles associated with each drug as a monotherapy, with no clinically significant drug-drug interactions observed with the combination.
April 08, 2021
Study indicates patients with ovarian cancer frequently receive aggressive end-of-life care despite industry guidelines that emphasize quality of life for those with advanced disease.
April 06, 2021
Guidelines typically recommend debulking surgery, plus systemic chemotherapy for most patients.
March 23, 2021
The company received Fast Track designation from the FDA for GEN-1, a DNA-mediated interleukin-12 (IL-12) immunotherapy.
February 23, 2021
The FDA has granted a fast track designation to the DNA-mediated interleukin-12 immunotherapy GEN-1 for use in the treatment of patients with advanced ovarian cancer.
December 21, 2020
Rucaparib is an oral, small molecule inhibitor being developed in multiple tumor types, including ovarian and metastatic castration-resistant prostate cancers.
October 28, 2020
FDA approves FoundationOne Liquid CDx as a companion diagnostic for alpelisib in advanced or metastatic breast cancer, rucaparib in advanced ovarian cancer, and alectinib in a specific type of metastatic non–small cell lung cancer.
September 04, 2020
A first-in-class targeted therapy, VB-111 is administered by intravenous infusion once every 6 to 8 weeks.
August 07, 2020
Several recent studies presented at the virtual SGO 2020 Annual Meeting on Women’s Cancer looked into veliparib, a potential anticancer PARP inhibitor, for treatment of various types of ovarian cancer.